Related Experiment Videos
Losartan-induced hepatic injury
Fehmi Tabak1, Ali Mert, Resat Ozaras
1Department of Clinical Bacteriology and Infectious Diseases, Cerrahpasa Medical Faculty, Istanbul University, Beylerbeyi 81210 Istanbul, Turkey. fehmitabak@hotmail.com
Journal of Clinical Gastroenterology
|April 18, 2002
Summary
Losartan, used for hypertension, can rarely cause severe liver damage and fibrosis. Clinicians should monitor for this rare hepatic toxicity, particularly early in treatment.
Area of Science:
- Pharmacology
- Hepatology
- Cardiovascular Medicine
Background:
- Losartan is a widely prescribed angiotensin II receptor antagonist for hypertension.
- Clinical use suggests a favorable safety profile for losartan.
- Drug-induced liver injury (DILI) is a known concern with various medications.
Observation:
- This report details a rare case of severe hepatic toxicity and fibrosis linked to losartan.
- A review of existing literature identified four prior cases of similar losartan-associated liver injury.
- The observed toxicity manifested as significant liver damage and fibrotic changes.
Findings:
- Losartan, despite its general safety, can induce severe hepatic toxicity in susceptible individuals.
- Hepatic injury associated with losartan appears to be an idiosyncratic reaction.
- Fibrosis development indicates a potentially serious and progressive liver response.
Implications:
- Awareness of losartan-induced hepatic toxicity is crucial for healthcare providers.
- Vigilance for liver injury is particularly important during the initial treatment phase with losartan.
- This underscores the need for careful patient monitoring and prompt recognition of adverse drug reactions in hypertension management.